|
Price: $16.1600
$0.10 
0.623%
|
| Day's High:
| $16.34
| Week Perf:
| 8.17 %
|
| Day's Low: |
$ 15.84 |
30 Day Perf: |
9.26 % |
| Volume (M): |
3,287 |
52 Wk High: |
$ 20.69 |
| Volume (M$): |
$ 53,113 |
52 Wk Avg: |
$11.05 |
| Open: |
$16.16 |
52 Wk Low: |
$3.61 |
|
|
| Market Capitalization (Millions $) |
4,647 |
| Shares
Outstanding (Millions) |
288 |
| Employees |
200 |
| Revenues (TTM) (Millions $) |
288 |
| Net Income (TTM) (Millions $) |
-74 |
| Cash Flow (TTM) (Millions $) |
296 |
| Capital Exp. (TTM) (Millions $) |
2 |
Immunogen Inc
Immunogen Inc. is a biotechnology company that specializes in the development of targeted cancer therapies. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Immunogen's core technology is its Antibody Drug Conjugate (ADC) technology, which involves combining potent cancer cell-killing agents called cytotoxic agents with cancer-targeting antibodies. The resulting ADCs are designed to selectively bind to cancer cells, delivering the cytotoxic agents directly to the cancer cells and minimizing damage to healthy cells. This targeted approach aims to improve the efficacy and safety of cancer treatments.
Immunogen has a long history of developing ADCs and its technology platform has been used to develop several clinical-stage products, including mirvetuximab soravtansine, IMGN779, IMGN632, and IMGN15 Mirvetuximab soravtansine is a promising product that targets folate receptor alpha (FR'), which is found on the surface of various types of cancer cells, including ovarian cancer. The drug has demonstrated clinical activity in patients with FR'-positive ovarian cancer and is currently in Phase 3 clinical trials.
In addition to its internal pipeline, Immunogen partners with other companies to develop ADCs using its technology. Some of its notable partnerships include collaborations with Roche, Sanofi, and Takeda.
Immunogen has a strong intellectual property portfolio, with numerous patents covering its ADC technology and processes. The company's technology and products have been recognized with numerous awards and accolades, including the Galien Foundation's Best Biotechnology Product award and the Boston Business Journal's Best Places to Work award.
Overall, Immunogen Inc. is a leader in the development of targeted cancer therapies, with a strong focus on ADCs. Its technology platform and extensive pipeline make it a promising company in the biotechnology industry.
Company Address: 830 Winter Street Waltham 2451 MA
Company Phone Number: 895-0600 Stock Exchange / Ticker: NASDAQ IMGN
| IMGN is expected to report next financial results on February 29, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
|
Acer Therapeutics Inc
The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.
|
|
Baudax Bio Inc
Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.27 $ |
| Revenues (TTM) |
1 $
|
| Cash Flow (TTM) |
1.03 $ |
| Cash |
2.11 $
|
| Book Value |
1.95 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.27 $
|
| Revenues (TTM) |
1 $ |
| Cash Flow (TTM) |
1.03 $ |
| Cash |
2.11 $
|
| Book Value |
1.95 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
